망막분지정맥폐쇄에 합병된 황반부종에서 유리체강내 트리암시놀론주입술과 베바시주맙주입술의 비교

Intravitreal Triamcinolone Versus Bevacizumab for Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion

Purpose: To compare clinical outcomes after intravitreal injection of triamcinolone acetonide or bevacizumab for the treatment of macular edema secondary to branch retinal vein occlusion. Methods: Sixty-six patients received an intravitreal injection of either triamcinolone acetonide or bevacizumab. Patients were retrospectively reviewed. Thirty-three out of 66 patients were treated with an intravitreal injection of triamcinolone acetonide, while the other 33 patients received a bevacizumab injection. All patients underwent a visual acuity test, optical coherence tomography imaging and ophthalmoscopic examination throughout the follow-up. Results: In the triamcinolone group, central macular thickness (CMT) decreased from 496.69 ± 153.01 μm at baseline to 313.06 ± 150.14 μm at the six-month follow-up visit, while in the bevacizumab group, CMT decreased from 441.30 ± 185.79 μm to 295.67 ± 188.80 μm (p＜0.05). In the triamcinolone group, best-corrected visual acuity (BCVA) improved from logMAR 0.92 ± 0.70 at baseline to logMAR 0.53 ± 0.43 at the six-month follow-up visit, and in the bevacizumab group, BCVA improved from logMAR 0.74 ± 0.47 to logMAR 0.34 ± 0.33 (p＜0.05). Conclusions: The therapeutic effects of intravitreal triamcinolone acetonide showed no significant differences compared with those of intravitreal bevacizumab with regard to anatomical and functional outcomes. J Korean Ophthalmol Soc 2010;51(8):1071-1076